Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage pharmaceutical company formed to leverage decades of leading research in lung injury and disease due to fibrosis by pursuing niche, orphan drug indications for which there is no current effective therapeutic option. The company is pioneering the development and commercialization of safe and effective drugs for the non-surgical treatment of fibrosis in and around the lungs: LTI-03 for Idiopathic Pulmonary Fibrosis and LTI-01 for Pleural Effusion with Loculation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/06/17 | $14,300,000 | Series B |
Bios Partners UT Horizon Fund | undisclosed |
